These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 7956941)
1. A conserved carboxy-terminal subdomain is important for ligand interpretation and transactivation by nuclear receptors. Lanz RB; Rusconi S Endocrinology; 1994 Nov; 135(5):2183-95. PubMed ID: 7956941 [TBL] [Abstract][Full Text] [Related]
2. Role of the C terminus of the glucocorticoid receptor in hormone binding and agonist/antagonist discrimination. Zhang S; Liang X; Danielsen M Mol Endocrinol; 1996 Jan; 10(1):24-34. PubMed ID: 8838142 [TBL] [Abstract][Full Text] [Related]
3. Mutant and wild-type androgen receptors exhibit cross-talk on androgen-, glucocorticoid-, and progesterone-mediated transcription. Yen PM; Liu Y; Palvimo JJ; Trifiro M; Whang J; Pinsky L; Jänne OA; Chin WW Mol Endocrinol; 1997 Feb; 11(2):162-71. PubMed ID: 9013763 [TBL] [Abstract][Full Text] [Related]
4. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Lu NZ; Wardell SE; Burnstein KL; Defranco D; Fuller PJ; Giguere V; Hochberg RB; McKay L; Renoir JM; Weigel NL; Wilson EM; McDonnell DP; Cidlowski JA Pharmacol Rev; 2006 Dec; 58(4):782-97. PubMed ID: 17132855 [No Abstract] [Full Text] [Related]
5. Repression of p65 transcriptional activation by the glucocorticoid receptor in the absence of receptor-coactivator interactions. Wu J; Li Y; Dietz J; Lala DS Mol Endocrinol; 2004 Jan; 18(1):53-62. PubMed ID: 14551261 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of gene expression by steroid hormone receptors via a negative glucocorticoid response element: evidence for the involvement of DNA-binding and agonistic effects of the antiglucocorticoid/antiprogestin RU486. Cairns C; Cairns W; Okret S DNA Cell Biol; 1993 Oct; 12(8):695-702. PubMed ID: 8397827 [TBL] [Abstract][Full Text] [Related]
7. Pathologic human GR mutant has a transdominant negative effect on the wild-type GR by inhibiting its translocation into the nucleus: importance of the ligand-binding domain for intracellular GR trafficking. Kino T; Stauber RH; Resau JH; Pavlakis GN; Chrousos GP J Clin Endocrinol Metab; 2001 Nov; 86(11):5600-8. PubMed ID: 11701741 [TBL] [Abstract][Full Text] [Related]
8. A novel, C-terminal dominant negative mutation of the GR causes familial glucocorticoid resistance through abnormal interactions with p160 steroid receptor coactivators. Vottero A; Kino T; Combe H; Lecomte P; Chrousos GP J Clin Endocrinol Metab; 2002 Jun; 87(6):2658-67. PubMed ID: 12050230 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the novel progestin gestodene by receptor binding studies and transactivation assays. Fuhrmann U; Slater EP; Fritzemeier KH Contraception; 1995 Jan; 51(1):45-52. PubMed ID: 7750284 [TBL] [Abstract][Full Text] [Related]
10. Genetic analysis of the N-terminal end of the glucocorticoid receptor hormone binding domain. Milhon J; Kohli K; Stallcup MR J Steroid Biochem Mol Biol; 1994 Oct; 51(1-2):11-9. PubMed ID: 7947345 [TBL] [Abstract][Full Text] [Related]
11. Molecular identification and characterization of a and b forms of the glucocorticoid receptor. Yudt MR; Cidlowski JA Mol Endocrinol; 2001 Jul; 15(7):1093-103. PubMed ID: 11435610 [TBL] [Abstract][Full Text] [Related]
13. Residues in the ligand binding domain that confer progestin or glucocorticoid specificity and modulate the receptor transactivation capacity. Robin-Jagerschmidt C; Wurtz JM; Guillot B; Gofflo D; Benhamou B; Vergezac A; Ossart C; Moras D; Philibert D Mol Endocrinol; 2000 Jul; 14(7):1028-37. PubMed ID: 10894152 [TBL] [Abstract][Full Text] [Related]
14. Dissociation of steroid receptor coactivator 1 and nuclear receptor corepressor recruitment to the human glucocorticoid receptor by modification of the ligand-receptor interface: the role of tyrosine 735. Stevens A; Garside H; Berry A; Waters C; White A; Ray D Mol Endocrinol; 2003 May; 17(5):845-59. PubMed ID: 12569182 [TBL] [Abstract][Full Text] [Related]
15. Transcriptional control of steroid-regulated apoptosis in murine thymoma cells. Chapman MS; Askew DJ; Kuscuoglu U; Miesfeld RL Mol Endocrinol; 1996 Aug; 10(8):967-78. PubMed ID: 8843413 [TBL] [Abstract][Full Text] [Related]
16. The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Vegeto E; Allan GF; Schrader WT; Tsai MJ; McDonnell DP; O'Malley BW Cell; 1992 May; 69(4):703-13. PubMed ID: 1586949 [TBL] [Abstract][Full Text] [Related]
17. A novel point mutation in the ligand-binding domain (LBD) of the human glucocorticoid receptor (hGR) causing generalized glucocorticoid resistance: the importance of the C terminus of hGR LBD in conferring transactivational activity. Charmandari E; Raji A; Kino T; Ichijo T; Tiulpakov A; Zachman K; Chrousos GP J Clin Endocrinol Metab; 2005 Jun; 90(6):3696-705. PubMed ID: 15769988 [TBL] [Abstract][Full Text] [Related]
18. Separable features of the ligand-binding domain determine the differential subcellular localization and ligand-binding specificity of glucocorticoid receptor and progesterone receptor. Wan Y; Coxe KK; Thackray VG; Housley PR; Nordeen SK Mol Endocrinol; 2001 Jan; 15(1):17-31. PubMed ID: 11145736 [TBL] [Abstract][Full Text] [Related]
20. Identification of amino acids in the tau 2-region of the mouse glucocorticoid receptor that contribute to hormone binding and transcriptional activation. Milhon J; Lee S; Kohli K; Chen D; Hong H; Stallcup MR Mol Endocrinol; 1997 Nov; 11(12):1795-805. PubMed ID: 9369447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]